CD274 and pneumonitis: For instance, Khunger et al. [36] reported that the incidence of any-grade pneumonitis was significantly higher at 3.6% (versus 1.3% with PD-L1 inhibitors, p < 0.01) for PD-1 inhibitors and that of grade ≥3 pneumonitis was 1.1% (versus 0.4% with PD-L1 inhibitors, p < 0.05) of NSCLC patients.